| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NEW YORK—Mid-August saw LifeSci Partners announce the launch of its newest division, LifeSci Strategic Partnering and Analytics, which is focused on supporting partnering and strategic consulting activities for clients exclusively within the life sciences.
 
The strategic partnering activities include facilitating in-licensing and out-licensing transactions and research and development collaborations, among other types of partnerships. As for the analytics part of the division, that offering will deliver primary and secondary market research and financial analyses to assist companies in understanding and effectively articulating asset value propositions to investors and strategic partners, and will guide internal development and capital allocation decisions.
 
The addition of the new division adds strategic partnering and market analytics to such previous offerings as investor relations, public relations, corporate communications, capital markets consulting and executive searches.
 
“LifeSci Partners continues to leverage its extensive relationships and unmatched domain expertise within the life sciences on behalf of our clients ... our newest division will address our clients’ strategic partnering needs, harnessing our extensive network of global relationships with senior executives and business development professionals at large and midsize life science companies,” said Dr. Andrew McDonald, co-founder of LifeSci Partners. “We recognize it is crucial for companies to properly assess the commercial potential and value proposition of their assets to support financing, partnering and internal decision-making activities. LifeSci Strategic Partnering and Analytics utilizes LifeSci’s expertise in financial modeling, physician surveys and KOL [key opinion leader] interviews to help companies define their market opportunity based on hard data, increasing the likelihood of attracting and securing resources necessary to bring novel technologies to market.”

Related Topics

Published In

Volume 14 - Issue 9 | September 2018

September 2018

September 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue